Clinical Trial Update: Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris [Phase 2]

View source ↗

Summary

A Phase II randomized, double-blind, placebo-controlled trial evaluating BMS-188667 (CTLA4Ig) in psoriasis vulgaris has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• BMS-188667 (CTLA4Ig) (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriasis Vulgaris | Phase 2 | Status: COMPLETED